ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for breast cancer patients after first treatment fails
Disease control Recruiting nowThis study is for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a common first treatment. The trial will test a combination of two drugs, fulvestrant and abemaciclib, after a short break from the previous treatmen…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New hope for advanced breast cancer: OPERA-02 trial tests promising drug combo
Disease control Recruiting nowThis phase 3 study tests whether a new drug called palazestrant, combined with ribociclib, works better than the standard treatment (letrozole plus ribociclib) for people with a common type of advanced breast cancer (ER+/HER2-). About 1,000 adults who have not had prior treatment…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three drugs (neratinib, an aromatase inhibitor, and trastuzumab) for 24 weeks before surgery can eliminate all signs of cancer in the breast tissue of people with ER-positive, HER2-positive breast cancer. About 30 postmenopausal wo…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Ruth O'Regan • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug, OP-1250, against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can delay cancer growth better than standard care. About 510 adults whose…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug cocktail aims to control advanced breast cancer
Disease control Recruiting nowThis early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adu…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Promising combo targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests whether adding everolimus to elacestrant works better than elacestrant alone for people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation). About 240 adults whose cancer has worsened after standard hormone therapy and CDK4/6 inhibitor…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: MedSIR • Aim: Disease control
Last updated May 12, 2026 13:41 UTC